Editorial Policy

Summary: Every article on GLP1 Alpha is anchored to primary sources, fact-checked against FDA labels and peer-reviewed trials, and dated. This page explains the standards we hold ourselves to and how to flag an error.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Why this page exists

GLP-1 medications affect people's health, weight, blood sugar, and money. Readers deserve to know how content on this site is researched, written, reviewed, and corrected, and where to push back when we get something wrong. This page is the canonical answer to those questions.

What we publish

GLP1 Alpha publishes reference articles about the GLP-1 receptor agonist class: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), and investigational entries like retatrutide. Articles cover mechanism, dosing, side effects, comparisons, costs, access pathways, and lifestyle considerations. We do not publish personal health stories, sponsored reviews of specific telehealth clinics, or content designed primarily to rank for a search term.

Sourcing standards

Every clinical claim on this site is anchored to a primary source. The acceptable source tiers, in order of preference:

  1. FDA-approved prescribing information for the drug in question (Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Rybelsus), accessed through accessdata.fda.gov.
  2. Peer-reviewed clinical trial papers in journals like the New England Journal of Medicine, JAMA, Lancet, Diabetes Care, and Obesity. Pivotal trials we cite by name include STEP-1 through STEP-8 for semaglutide weight loss, SUSTAIN-6 and SELECT for semaglutide cardiovascular outcomes, SURMOUNT-1 through SURMOUNT-5 for tirzepatide, and TRIUMPH for retatrutide.
  3. Regulatory and safety bulletins: FDA MedWatch, FDA Drug Shortage list, EMA assessment reports, and CDC clinical guidance.
  4. Manufacturer prescribing leaflets and patient information leaflets for current pricing, packaging, and dosing schedules.
  5. Reputable medical references: Drugs.com (for interaction and dosing summaries), the NIH Office of Dietary Supplements, UpToDate where we have access, and society guidelines from the ADA and AACE.

We do not use Wikipedia, news aggregators, or other secondary sources as the source of a medical fact. They are acceptable for context, history, or non-clinical framing, but a clinical claim must trace back to one of the tiers above.

Writing and editing standards

Articles are written to a consistent voice guide. The voice is plain, confident, and direct. We avoid hype language ("breakthrough," "miracle," "game-changer"), avoid the soft-hedging tone that pads health content ("it's important to note," "always consult your doctor before making any changes"), and avoid em dashes. We name what is uncertain rather than performing certainty we do not have.

Every article is reviewed for factual accuracy against its cited sources before publication, and again when material facts change. Each page carries a "last updated" date so readers can see how fresh the content is.

Medical review

GLP1 Alpha is an editorial reference site, not a clinical practice. The site does not currently retain a named board-certified medical reviewer of record. Where an article touches a topic that benefits from clinical input (specific dosing protocols, pediatric considerations, pregnancy, complex comorbidities), we say so in the article and direct readers to a licensed prescriber rather than answering questions that require an individualized clinical judgment.

We are in active conversation with clinicians about a formal medical review process and will name the reviewer here when that is in place.

Corrections policy

We correct factual errors promptly. The process:

  1. If you spot an error, an outdated statistic, a misattributed citation, or a broken source link, email us at the address on the About page.
  2. We verify the correction against the underlying source.
  3. If the correction stands, we update the article, update the "last updated" footer date, and submit the corrected URL to IndexNow so search engines refetch it.
  4. If the correction materially changes the article's conclusion, we add a brief "Updated:" note at the top of the article explaining what changed and when.

Editorial independence and conflicts of interest

GLP1 Alpha is not funded, sponsored, or operated by a pharmaceutical manufacturer, a telehealth clinic, or a compounding pharmacy. We have no equity in any GLP-1 product or service. Our revenue comes from (a) affiliate commissions on outbound links to telehealth and pharmacy partners, disclosed in the disclaimer, and (b) display advertising in some article footers.

Commercial relationships do not influence which medications we cover, which trials we cite, or what we say about safety, efficacy, or pricing. Partners do not preview articles before publication. Partners cannot pay to remove a side effect, an FDA warning, or a critical price comparison from an article. If a partner asks for that, we drop the partner, not the content.

Comments, user-generated content, and personal stories

We do not currently host article comments or user-submitted health stories. The reason is regulatory: unmoderated medical anecdotes can read as testimonials, and we do not want to publish individual outcome claims we cannot verify. If we add a comments system later, it will be moderated, disclosed, and clearly labeled as reader-submitted.

What we will not publish

  • Promotional content for specific compounding pharmacies, including affiliate offers from gray-market peptide sellers.
  • Content suggesting GLP-1 medications are safe in pregnancy or breastfeeding (the labels are clear; we do not contradict them).
  • Off-label dosing protocols that go beyond what the FDA label and published trial evidence support.
  • Articles aimed at minors. The GLP-1 pediatric evidence base is narrow and the editorial frame here is adult-focused.
  • Articles whose only purpose is to rank for a transactional keyword without addressing the underlying question.

Updates to this policy

This policy is itself versioned. When we change it substantively, we update the footer date and note the change in a short revision history below.

Revision history

  • 2026-05-19: First published.